Zobrazeno 1 - 10
of 23
pro vyhledávání: '"Elio Gregory, Pizzutilo"'
Autor:
Elio Gregory Pizzutilo, MD, Alberto Giuseppe Agostara, MD, Laura Roazzi, MD, Rebecca Romanò, MD, Valentina Motta, PhD, Calogero Lauricella, PhD, Giovanna Marrapese, PhD, Giulio Cerea, MD, Diego Signorelli, MD, PhD, Silvio Marco Veronese, PhD, Laura Giuseppina Giannetta, MD, Andrea Sartore-Bianchi, MD, Salvatore Siena, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 11, Pp 100555- (2023)
ROS1 tyrosine kinase inhibitors (TKIs) were found to provide a substantial clinical benefit for patients with advanced ROS1-positive (ROS1+) NSCLC. Nevertheless, TKI resistance inevitably develops with different mechanisms, preventing prolonged respo
Externí odkaz:
https://doaj.org/article/d61ce692b70b43e5b3a2d9ee7b951f11
Autor:
Giuseppe Viscardi, Fabiana Vitiello, Alberto Servetto, Valerio Gristina, Elio Gregory Pizzutilo, Maria Anna Canciello, Paola Maria Medusa, Fabio Salomone, Gaetano Di Guida, Mariano Mollica, Luigi Aronne, Roberto Scaramuzzi, Filomena Napolitano, Ciro Battiloro, Francesca Caputo, Marina Gilli, Giuseppe Totaro, Carlo Curcio, Danilo Rocco, Vincenzo Montesarchio
Publikováno v:
Cancers, Vol 14, Iss 23, p 5810 (2022)
Lung cancer is the leading cause of cancer-related death worldwide. Since prognosis of early-stage non-small cell lung cancer (NSCLC) remains dismal for common relapses after curative surgery, considerable efforts are currently focused on bringing im
Externí odkaz:
https://doaj.org/article/18d64bda6c384a0ca4f6a82defd63158
Autor:
Gianluca Gazzaniga, Federica Villa, Federica Tosi, Elio Gregory Pizzutilo, Stefano Colla, Stefano D’Onghia, Giusy Di Sanza, Giulia Fornasier, Michele Gringeri, Maria Victoria Lucatelli, Giulia Mosini, Arianna Pani, Salvatore Siena, Francesco Scaglione, Andrea Sartore-Bianchi
Publikováno v:
Cancers, Vol 14, Iss 7, p 1666 (2022)
Pneumatosis intestinalis (PI) is a rare condition due to the presence of gas within the bowel wall; it is mainly caused by endoscopic procedures, infections and other gastrointestinal diseases. Oncological therapies have been reported to be a cause o
Externí odkaz:
https://doaj.org/article/207814df851d4499a9a0b549c9ad60aa
Autor:
Andrea Sartore-Bianchi, Alberto Giuseppe Agostara, Giorgio Patelli, Gianluca Mauri, Elio Gregory Pizzutilo, Salvatore Siena
Publikováno v:
Digestive and Liver Disease. 54:1291-1303
Cancer treatment is increasingly focused on targeting molecular alterations identified across different tumor histologies. While some oncogenic drivers such as microsatellite instability (MSI) and NTRK fusions are actionable with the very same approa
Autor:
Elio Gregory. Pizzutilo, Rebecca Romanò, Laura Roazzi, Alberto Giuseppe. Agostara, Sara Oresti, Annalisa Zeppellini, Laura Giannetta, Giulio Cerea, Diego Signorelli, Salvatore Siena, Andrea Sartore-Bianchi
Publikováno v:
Cancer Research.
Cancer immunotherapy, largely represented by immune checkpoint inhibitors (ICIs), has led to substantial changes in preclinical cancer research and clinical oncology practice over the past decade. However, the efficacy and toxicity profiles of ICIs r
Autor:
Elio Gregory Pizzutilo, Martino Pedrani, Alessio Amatu, Lorenzo Ruggieri, Calogero Lauricella, Silvio Marco Veronese, Diego Signorelli, Giulio Cerea, Laura Giannetta, Salvatore Siena, Andrea Sartore-Bianchi
Publikováno v:
Cancers, Vol 13, Iss 9, p 2265 (2021)
Background: The potential added value of liquid biopsy (LB) is not well determined in the case of small cell lung cancer (SCLC), an aggressive tumor that can occur either de novo or from the histologic transformation of non-small cell lung cancer (NS
Externí odkaz:
https://doaj.org/article/5439528c2a8342a591cb40c433b2de83
Autor:
Alessio Amatu, Marta Schirripa, Federica Tosi, Sara Lonardi, Katia Bencardino, Erica Bonazzina, Laura Palmeri, Damiano Alfio Patanè, Elio Gregory Pizzutilo, Benedetta Mussolin, Francesca Bergamo, Giulia Alberti, Rossana Intini, Letizia Procaccio, Marco Arese, Silvia Marsoni, Michele Nichelatti, Vittorina Zagonel, Salvatore Siena, Alberto Bardelli, Fotios Loupakis, Federica Di Nicolantonio, Andrea Sartore-Bianchi, Ludovic Barault
Publikováno v:
Frontiers in Oncology, Vol 9 (2019)
Background: Regorafenib improves progression free survival (PFS) in a subset of metastatic colorectal cancer (mCRC) patients, although no biomarkers of efficacy are available. Circulating methylated DNA (cmDNA) assessed by a five-gene panel was previ
Externí odkaz:
https://doaj.org/article/03adbb2e3faf4c54b1f03312367d97e5
Autor:
Fausto Petrelli, Diego Signorelli, Michele Ghidini, Antonio Ghidini, Elio Gregory Pizzutilo, Lorenzo Ruggieri, Mary Cabiddu, Karen Borgonovo, Giuseppina Dognini, Matteo Brighenti, Alessandro De Toma, Erika Rijavec, Marina Chiara Garassino, Francesco Grossi, Gianluca Tomasello
Publikováno v:
Cancers, Vol 12, Iss 3, p 546 (2020)
Immune checkpoint inhibitors (ICIs) can elicit toxicities by inhibiting negative regulators of adaptive immunity. Sometimes, management of toxicities may require systemic glucocorticoids. We performed a systematic review and meta-analysis of publishe
Externí odkaz:
https://doaj.org/article/e5a3f4c61490404bb58ba9f8eb3524b0
Autor:
Diego Signorelli, Elio Gregory Pizzutilo, Alfredo Addeo, Miriam Garaffa, Fausto Roila, Guido Bellezza, Giulio Metro, Martina Mandarano, Giulio Cerea, Alex Friedlaender, Laura Giannetta
Publikováno v:
Hum Vaccin Immunother
Unresectable malignant pleural mesothelioma (MPM) is an aggressive disease with a 5-year survival rate of approximately 10%. Recent data suggest that MPM is an immunologically active tumor, in which checkpoint inhibition through the blockade of the a
Autor:
Caterina, Vaghi, Gianluca, Mauri, Alberto Giuseppe, Agostara, Giorgio, Patelli, Elio Gregory, Pizzutilo, Yoshiaki, Nakamura, Takayuki, Yoshino, Salvatore, Siena, Andrea, Sartore-Bianchi
Publikováno v:
Cancer Treatment Reviews. 112:102488
ERBB2 amplification is a driver oncogenic alteration in many cancers and it has recently been incorporated among therapeutically actionable biomarkers also in metastatic colorectal cancer (mCRC). In contrast, the role of ERBB2 point mutations, which